About us

Advanced AI diagnosis for every hospital

Phantomics was founded with a vision to overcome cardiovascular diseases through accurate and reliable AI-driven diagnostic imaging technologies. Established in 2019 by Professor Byoung Wook Choi of the Radiology Department at Yonsei University Severance Hospital and Dr. Pan Ki Kim, an imaging physicist, Phantomics draws upon years of expertise in cardiac imaging. The name "Phantomics" combines "Phantom" and "Omics" to encapsulate the company's mission: acting as a virtual assistant that autonomously delivers essential diagnostic information to physicians.

Phantomics aspires to create a world where humanity is free from the burden of major diseases, including cardiovascular conditions, through cutting-edge AI diagnostic imaging technologies. By integrating advanced artificial intelligence with medical imaging, the company is developing next-generation solutions capable of detecting disease biomarkers and predicting prognoses. Through its AI-powered diagnostic platforms, Phantomics aims to revolutionize early detection and prevention of cardiovascular and other critical diseases, striving to enable every hospital worldwide to access state-of-the-art medical technologies.

Virtual fellow: faster analysis, easier diagnosis

Cardiovascular disease, the leading cause of death worldwide and the second-highest in South Korea after cancer, is a condition where early detection and diagnosis are critical for prevention. While cardiac MRI and CT are essential for effective early diagnosis, the constantly moving nature of the heart presents challenges, including lengthy imaging times and the need for advanced expertise. Phantomics is dedicated to overcoming these limitations by lowering the barriers of cardiac MRI and CT through standardized AI, creating a win-win ecosystem for both medical professionals and patients.

Phantomics' flagship solution, Myomics, is actively utilized in over 20 major general hospitals and secondary hospitals across South Korea, as well as in 19 international medical institutions. Its utility has been consistently proven in clinical settings. Myomics has received regulatory approvals from the Thai FDA, the Malaysian MDA, the Taiwan FDA and Japan's PMDA, as well as U.S. FDA clearance, ensuring its safety and reliability. In 2024, Phantomics became the first company in the Korean AI medical imaging industry to win the CES 2024 Innovation Award and the FIX Innovation Awards Grand Prize, further validating the outstanding innovation of its core technology in both domestic and global markets.

Trusted by

Milestones

2019 – today

2026

08

MFDS Class 3 digital medical device approval (Angiomics ER)

2025

11

Japan PMDA approval (Myomics) and Japan JRS AI software certification

10

KHF 2025 Best Innovation Award; industry-academia collaboration with Yonsei University's Digital Healthcare program

09

Strategic MOU with GE HealthCare Korea

06

Strategic MOU with Siemens Healthineers

03

U.S. FDA 510(k) clearance for enhanced AI-powered cardiac MRI analysis

2024

10

FIX 2024 Innovation Award (ABB category)

07

Selected as a Seoul-type Strong SME

06

Established a subsidiary in Boston, USA

05

Selected for the Ministry of SMEs and Startups' Super Gap 1000+ program; Taiwan medical device approval (Myomics)

01

CES 2024 Innovation Award in Digital Health

2023

11

Thailand medical device approval (Myomics); MFDS Class 2 approvals (Angiomics, Angiomics Seg)

10

Designated a Hi-Seoul Company

09

Certified as an Excellent Technology Evaluation Company; EN ISO 13485:2016 certification

2022

11

MFDS Class 2 approval (Myomics X-01); Series A funding (Daily Partners, Bluepoint Partners)

04

MFDS Class 2 approval (Myomics-CINE)

2021

11

MFDS Class 2 approvals (Myomics-T1, Myomics-T2); U.S. FDA 510(k) clearance (Myomics-Q)

10

Designated a Military Service Exemption Company

2020

09

MFDS Class 2 approval (Myomics)

05

GMP certification

04

Established the corporate research institute; certified as a venture company

2019

09

Founded Phantomics Co., Ltd. (CEOs Byoung Wook Choi, Pan Ki Kim)

Leadership

BW

Byoung Wook Choi, M.D.

Co-founder & CEO · Professor of Radiology, Yonsei University Severance Hospital

A cardiac imaging specialist who has led cardiovascular radiology at Severance Hospital and founded Phantomics to bring expert-level cardiac diagnosis to every hospital.

PK

Pan Ki Kim, Ph.D.

Co-founder & CEO · Imaging physicist

An MRI physicist specializing in quantitative cardiac imaging and standardization, leading product, regulatory and global business at Phantomics.

See Myomics and Angiomics in action.

Request a demo, discuss a clinical study or explore a partnership. Our team in Seoul and Boston will get back to you.

⚡ Made with pagesss